Compare Inovio Pharmaceuticals Inc (INO) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.11 (market cap $119.42M), while Invesco S&P 500 Low Volatility ETF trades at $71.97 (market cap $7.00B). The key difference: Invesco S&P 500 Low Volatility ETF is far larger — about 58.6× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is more actively traded (2,789,649 versus 1,622,563). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| INO | SPLV | |
|---|---|---|
Market Cap | $119.42M | $7.00B |
Volume | 2,789,649 | 1,622,563 |
Sector | Health | — |
52-Week High | $2.65 | $77.97 |
52-Week Low | $0.66 | $70.30 |
Typical Hold Time | 43 Days | 123 Days |
Enterprise Value | $90.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
SPLV trades at $71.22, down 0.71% with a bearish technical signal from moving averages. The ETF's sector overweights in Utilities, Real Estate, and Financials have contributed to underperformance versus the S&P 500. Recent dividend payments of $0.14 per share were distributed in July and September 2026, while technical indicators show mixed signals with neutral RSI readings but strong bearish ADX momentum.
The outlook remains challenged by sector headwinds and unappealing growth-adjusted valuation at 19.5x P/E. Key risks include continued underperformance relative to broader market and sensitivity to interest rate movements. Opportunities exist for investors seeking low-volatility exposure during market uncertainty, though near-term catalysts appear limited.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
